Late-stage biotech Relypsa sets terms for $120 million IPO

By
A A A

Relypsa, which is developing treatments for renal, cardiovascular and metabolic diseases, announced terms for its IPO on Friday. The Redwood City, CA-based company plans to raise $120 million by offering 6.9 million shares at a price range of $16 to $19. At the midpoint of the proposed range, Relypsa would command a market value of $502 million.

Relypsa, which was founded in 2007, plans to list on the NASDAQ under the symbol RLYP. Relypsa initially filed confidentially on August 2, 2013. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RLYP

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com